News Between Reporter

A randomized trial conducted to test the efficacy of perioperative pembrolizumab in operable non-small cell lung cancer (NSCLC) has shown positive results. The trial showed a 42% reduction in risk for disease recurrence or death, thereby supporting the use of PD-1 checkpoint inhibitor in stage II-III NSCLC. Although the trial did not show a significant
A phase III trial conducted by SWOG S1826 has revealed that the immune checkpoint inhibitor nivolumab (Opdivo) is more effective than brentuximab vedotin (Adcetris) in reducing disease progression or death in newly diagnosed adults and adolescents with advanced-stage classical Hodgkin lymphoma (cHL). Research Findings The trial involved over 976 patients with newly diagnosed stage III-IV